VENU Holding Corp. (NYSE American: VENU) CEO JW Roth breaks down why municipalities actively compete to land VENU projects. Roth explains that every VENU project is structured as a partnership with the municipality, which contributes real estate, cash, and tax incentives — financing he says is non-dilutive to shareholders. He states the arrangement works both ways: VENU's venues bring an economic impact to the surrounding area, driving activity for restaurants and hospitality businesses nearby, which he calls a tax driver for the city. 🔗 Watch the clip: redchip.news/4xCoYsV VENU Holding Corp. is a client of RedChip. Not investment advice. Do your own due diligence. $TKO $MSGE $LYV $SPHR

Featured in RedChip Investor Interview: TransCode Therapeutics (Nasdaq: RNAZ) TransCode's CEO lays out the company's new corporate strategy: a three-platform oncology business spanning RNA therapeutics, cancer vaccines, and immuno-oncology, built out through the recent acquisition of a preclinical oncology company and licensing of an immunology pipeline. Watch the full interview to hear how the three-platform approach is meant to create multiple paths to value. 👉 redchip.news/4xX4WJj TransCode Therapeutics is a client of RedChip. Not investment advice. Do your own due diligence. $MRNA $ARWR $ALNY $IONS $SLN $SRPT

RedChip Exclusive Interview with Bimergen Energy (NYSE-A: BESS): Co-CEO Bob Brilon Breaks Down Bimergen's Backing, BESS Pipeline, and Scalable Growth Strategy Utility-scale battery storage is one of the fastest-growing segments in energy, and @BimergenEnergy is stepping up with a 2GW pipeline, equity commitment, and contract-backed revenue model. Watch our full interview now: redchip.news/3MYl23K Bimergen Energy is a client of RedChip. Not investment advice. Do your own due diligence. $NEE $FLNC $BE $ENPH $TSLA $GNRC

RedChip Overview: ASP Isotopes' Critical Materials Growth Strategy — ASP Isotopes (Nasdaq: ASPI) is targeting critical supply chains including nuclear medicine, nuclear fuel, semiconductors, and advanced materials. RedChip produced an overview featuring CEO Paul Mann, who discussed the company's growth strategy. What was covered: - The company's build-out of three plants in South Africa over three years - An expected commercial ramp in 2026 - A U.S. expansion strategy aimed at securing supply chains historically sourced from Russia - The company's positioning across multiple end markets with geopolitical relevance Watch our full ASPI investor overview: redchip.news/4eoGlGE ASP Isotopes is a client of RedChip. Not investment advice. Do your own due diligence. $SMR $NNE $OKLO $UUUU $CEG $VST $CCJ $UEC $LEU $GEV $BEP

Where does Amazon get the copper to build its AI data centers? Meet Gunnison Copper (TSX: GCU) (OTCQB: GCUMF) one of its newest suppliers... This week, Interior Secretary Doug Burgum and Congressman Juan Ciscomani [AZ] visited Gunnison's Johnson Camp mine. The day ended with a red, white and blue production blast. Read more 👉 redchip.news/3UgviYG $GCU $GCUMF $GUNN $AMZN $RIO $COPX $FCX

🧬 Recently on RedChip's Interview Series: Anixa Biosciences (Nasdaq: ANIX) CEO Dr. Amit Kumar discusses the company's breast cancer vaccine program in a new interview, joined by Sherry, a patient who participated in the vaccine's Phase 1 trial. Dr. Kumar describes the vaccine, developed in partnership with Cleveland Clinic and the U.S. Department of Defense, as designed for three potential uses: treating patients with breast cancer, preventing recurrence in survivors, and primary prevention in patients who have never had the disease. He notes it's a traditional peptide-based vaccine intended for broad use, distinguishing it from personalized mRNA vaccine approaches like the one recently reported in Phase 3 melanoma data from Merck and Moderna. Dr. Kumar states the company's next steps are Phase 2 studies, followed by Phase 3. 📌 What the Interview Covers: - The vaccine's three intended uses: treatment, recurrence prevention, and primary prevention - How the peptide-based approach differs from personalized mRNA cancer vaccines - Planned next steps: Phase 2 studies followed by Phase 3 - Sherry's account of her diagnosis, treatment, and Phase 1 trial participation - Dr. Kumar's comments on the vaccine's potential longer-term impact on breast cancer treatment 🔗 Watch the full interview: youtube.com/watch?v=jCUvJY2b… Anixa Bioscience is a client of RedChip. Not investment advice. Do your own due diligence. $MRNA $BNTX $REGN $CRSP $LEGN $RCUS $VIR $NTRA $EXAS $NTLA $EXEL

🏦 Hawkeye (OTC: HWKE) Digital President David Wachsman explains what sets the company apart: merchant banking. Unlike a traditional investment bank that just advises, Hawkeye puts its own capital into the companies it works with — taking minority equity stakes while helping them build toward a Wall Street journey. 🔗 The bet: many of the best companies in digital assets and other breakthrough tech will eventually need to get to public markets, and Hawkeye wants to be the firm sourcing them, investing in them, and guiding them there. Watch the full webinar: redchip.news/4hcc1ip #MerchantBanking #DigitalAssets #PrivateEquity #Fintech #HWKE #CapitalMarkets

RedChip Overview: Trinity Biotech's Trinovium Subsidiary and AI Data Center Cooling The AI boom is racing to scale — and it burns hot. Data centers are cooling millions of microchips to fight the heat and corrosion that kill hardware. RedChip produced an overview of Trinity Biotech (Nasdaq: TRIB) and its new subsidiary, Trinovium, built to address that challenge. What was covered: - A high-precision, direct-to-chip cooling solution built on Trinity Biotech's experience in high-purity fluids and analytics - The company's approach to redeploying existing U.S. and EU manufacturing capacity for cooling fluid production - A planned fluid health and system intelligence platform designed to monitor corrosion, particulate contamination, and microbial growth Watch the overview now: redchip.news/4bsgeN9 Trinity Biotech is a client of RedChip. Not investment advice. Do your own due diligence. $VRT $MOD $EQIX $DLR $HON $NVDA

Venu Holding (NYSE: VENU) Advances Texas Growth Strategy with $60 Million Land Transaction Read more: redchip.com/news/63918938207…

🩺 Millions of patients with post-acute infection syndromes — including Long COVID, ME/CFS, and post-treatment Lyme disease — are still being diagnosed largely through symptoms and exclusion, with no widely adopted objective test to confirm what's actually going on. 📊 Virax Biolabs (Nasdaq: VRAX) estimates this category carries a $25 billion annual economic burden in the U.S., affecting roughly 21 million people with about 2.5 million new cases every year. Full webinar replay: redchip.news/4riTXaZ Virax Biolabs is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $NVO $PFE $REGN $JNJ

🎵 Alliance Entertainment (Nasdaq: AENT) CEO Jeff Walker opens this interview by pushing back on a common investor assumption: that physical entertainment is a shrinking category because everything's available digitally. His counter is simple — people aren't buying physical media as a streaming substitute, they're collecting. Fans want the vinyl, the CD, the SteelBook on their shelf. Scale is the other half of the story. Alliance operates from an almost 900,000-square-foot warehouse in Kentucky, stocks more than 340,000 SKUs, and distributes across more than 35,000 retail and e-commerce storefronts, a business Walker frames as a long-term opportunity to stay connected to a product well past the original sale. Walker also notes Alliance currently has analyst coverage with buy ratings — a detail worth digging into further on your own, alongside the rest of the fundamentals discussed here. 🔗 Watch the full interview: youtube.com/watch?v=9JWxP2Of… Alliance Entertainment is a client of RedChip. Not investment advice. Do your own due diligence. $AENT $FNKO $SONY $DIS $PARA $WBD $NTDOY

🧬 In this overview, Biovie Inc. (Nasdaq: BIVI) CEO Cuong Do recaps two Phase 2 clinical trial readouts BioVie has delivered within roughly 30 days of each other, both for lead candidate bezisterim. The first, in Parkinson's disease, shows the drug's potential to address both motor and non-motor symptoms — a distinction Do frames as significant, since most Parkinson's treatments target motor symptoms alone. He also points to the possibility that bezisterim could become the first drug to modify the disease's progression rather than just manage symptoms. The second readout, in Long COVID, found that patients experienced statistically significant, clinically meaningful improvement across fatigue, malaise, and brain fog. Looking ahead, Do says BioVie will continue analyzing the data from both trials and begin engaging with the FDA on Phase 3 trial design for both the Parkinson's and Long COVID programs. 🔗 Watch the overview: youtube.com/watch?v=Cgfr6PDx… Biovie Inc. is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $NVO $PFE $REGN

Rare earth elements are essential inputs for advanced industrial systems, including power generation, communications infrastructure, defense technologies, and high-performance manufacturing. RedChip's overview of Avalon Advanced Materials Inc. (TSX: AVL | OTCQB: AVLNF) explores the company and its work advancing the Nechalacho Rare Earth Project, which the company describes as one of the most strategically significant rare earth assets in North America, containing both light and heavy rare earth content. 🔗 Learn more about Avalon's rare earth strategy: redchip.news/43hXOtY Avalon Advanced Materials is a client of RedChip. Not investment advice. Do your own due diligence. $RIO $CE $FMC $MP $UUUU $ALB $USAR

On Redchip's Interview Series: NioCorp (Nasdaq: NB) published an updated feasibility study for the Elk Creek Project, and CEO Mark Smith sat down to explain why it reshapes the investment case — not just the resource, but the economics and the national security backdrop behind it. Watch the full interview: redchip.news/46xTiZM NioCorp is a client of RedChip. Not investment advice. Do your own due diligence. $MP $PPTA $TECK $KGC $HL $NST $CTGO

Join Our Conference! Powering The Future: The Next Generation of Energy Infrastructure Live Now! xitter.cf/i/broadcasts/1rGmqpMNr…

On RedChip's recent Webinar OBook Holdings (Nasdaq: OWLS) founder and CEO Darren Wang lays out his vision for the future of global payments. Wang points to stock exchanges tokenizing shares and brokerages needing stablecoin gateways as early signs of a much larger shift, one where prediction markets, cross-border payments, and everyday transactions all run on stablecoin rails. Wang says the goal is to build invisible infrastructure so banks and fintech companies, not just crypto-native platforms, can move money globally with the same ease people expect today. He points to enterprise clients already moving tens of millions of dollars a month through OwlTing's network as an early proof point of that shift. Watch the full interview: redchip.news/4wpqkFT OBook Holdings is a client of RedChip. Not investment advice. Do your own due diligence. $COIN $PYPL $XYZ $NATL $MARA $RIOT $MSTR $NVDA

🚨 Starting in One Hour: RedChip’s Powering the Future Investor Conference, TODAY at 9:30 AM ET RedChip’s Powering the Future Investor Conference begins in one hour. Join CEOs from publicly traded companies across LNG, nuclear, renewables, battery storage, critical minerals and infrastructure as they present live on the next generation of energy infrastructure. Registration takes less than a minute. Register now and join us at 9:30 AM ET. 🔗 Register here: redchip.news/3Tk2myz #RedChip #PoweringTheFuture #InvestorConference #EnergyInfrastructure #LNG #Nuclear #RenewableEnergy #BatteryStorage #CriticalMinerals #SmallCapStocks

Nexalin Technology (Nasdaq: NXL) CEO Mark White explains how a doctor's recommendation turns into in-home treatment with the company's HALO headset. White describes the process: a patient sets up a telehealth psychiatry appointment through Nexalin's virtual clinic, and the doctor completes a full diagnosis remotely. If the doctor recommends the HALO, the device ships to the patient's home, arriving as soon as the next day. The patient scans a QR code to download the app, enters their patient ID, and the doctor's protocol — uploaded to the cloud during the appointment — loads directly into the headset. White states the doctor can then monitor compliance, check that the equipment is working, and track treatment response throughout the 4-6 week course, all without the patient visiting a clinic. 🔗 Learn more about Nexalin Technology: redchip.news/46GWwKv Nexalin Technology is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $AMGN $REGN $GILD $MRNA

📣 Hawkeye Digital (OTCQB: HWKE) Live Investor Webinar: Thursday, November 5 at 4:15 PM ET Hawkeye Digital is building a merchant banking and private equity platform dedicated to the digital asset economy, which management believes could become one of the first of its kind to be publicly traded. Instead of depending on the price of digital assets, the company aims to profit from the growth of the whole ecosystem as institutional adoption accelerates. Mark your calendar to hear management outline the model and the path ahead. 🔍 Why investors are watching: Boston Consulting Group projects tokenized real-world assets could grow into a $14 trillion market by 2030 A platform that combines merchant banking, private equity and strategic advisory services focused on digital assets Led by President David Wachsman, who founded the blockchain-focused strategic communications and advisory firm Wachsman in 2015 Wachsman has advised Ripple, Circle, Tether, Binance, OKX, Solana Foundation and ConsenSys The company is working toward an uplisting to a national exchange Register now to reserve your spot for the live presentation and Q&A. 🔗 Register here: redchip.news/4Bh8Uix #HWKE #HawkeyeDigital #DigitalAssets #Blockchain #Crypto #Tokenization #PrivateEquity #OTCQB #InvestorWebinar #SmallCapInvesting #RedChip

Venu Holding Corporation (NYSE American: VENU): Featured in RedChip Investor Interview — CEO JW Roth on Venue Development Model RedChip conducted an interview with Founder, Chairman, and CEO JW Roth of Venu Holding Corporation. Roth discussed the company's approach to developing live entertainment venues and the financing structures involved. What Roth covers: - The company's public-private partnership model, including municipal contributions toward project development - Financing approaches including fractional ownership sales and sale-leaseback structures used to fund a portion of project costs - Revenue sources including sponsorship, naming rights, food and beverage, parking, and ticketing 🔗 Watch the full interview: redchip.news/4baCQ4p Venu Holding Corporation is a client of RedChip. Not investment advice. Do your own due diligence. #RedChip #RedChat #VENU #LiveEntertainment #RevenueGrowth #Investing #SmallCapStocks #Hospitality